Tagged with CCE

pharma As Director of the Netherlands’ association for innovative medicines, Gerard Schouw outlines new strategies to enhance the Dutch research climate; foster greater collaboration between all stakeholders and improve public perception of the industry. In light of the upcoming Dutch Presidency of the European Union, the Netherlands intends to lead the…

Pharma Mr. Finn Søndergaard, CEO of Intsel Chimos, an independent French laboratory with a long history of expertise in the import of medicines for patients in a therapeutic impasse, highlights Intsel Chimos’ emphasis on innovation and R&D and discusses the promising orphan drug the company is in the process of developing. He…

pharma The General Manager of Boehringer Ingelheim South Africa talks about changes that are required to the healthcare system, with far more government/private partnerships, helping to unlock the country´s potential, why South Africa acts as a springboard for many companies looking to develop their footprint in the region, making it the…

pharma The General Manager of Abbott’s Established Pharmaceuticals Division in South Africa, Gauta Phillip Mavundla illustrates how he is building the division’s presence within the region after the spinoff of AbbVie, while also highlighting branded generics as a key growth driver and how the company plans on expanding its capabilities in…

France PharmaBoardroom spoke to Fabrice Chouraqui, President of Novartis Latin America and Canada at the Financial Times LatAm Healthcare & Life Sciences Summit in September 2015. He emphasizes the criticality of access to innovation for patients in one of the world’s fastest-growing regions. You were appointed President of Novartis Latin America…

pharma The managing director of Adcock Ingram’s prescription business, Ashley Pearce highlights the division’s strategic placement within the group’s overall activities, and how he plans on leveraging partnerships with various multinationals, expand into biosimilars and grow the generics business into a market leading position. Adcock Ingram has undergone several strategic changes…

Pharma Peter Fuller provides us with an update on the integration of Covidien businesses, and explains how Medtronic is bringing innovation to South African patients and contributing to the improvement of the South African healthcare. Fuller is Vice President & General Manager of Medtronic South Africa, SADC & EAC.  In January 2015, Covidien was bought…

Pharma Beurs Van Berlage is an historic conference center in Amsterdam, hosting thousands of participants each year, many of them physicians, scientists, and professionals attending seminars, conferences, and meetings related to groundbreaking developments in medicine. The institution’s managing and commercial director discuss their organization’s suitability for hosting life science conferences. Could you…

strategic levels Umut Gökalp, managing director of Japan’s Sysmex in Turkey – a company specialising in in-vitro diagnostics – evaluates their approach to developing business opportunities in the Turkish medical device sector. He also describes how the company’s new reagent facility in Germany will help bolster it domestically and regionally. Can you tell us…

regulation Sevi Firat, Founding Partner of Firat Izgi discusses the legal challenges facing pharmaceutical companies looking to penetrate the healthcare market in Turkey, the evolution of the legal landscape and her expectations for the industry’s future. With pricing and regulations as the major challenges facing players within the Turkish pharma and…

medical devices The industry of medical devices is soaring in Mexico. The general manager of ConvaTec discusses strategic priorities, new approaches and how reduced time to market is feeding the double-digit growth of the company The last time we met you was back in 2012. What kept you busy over the past…

Novartis Novartis country president Peter Catalino discusses the need for Turkey to introduce financial investment incentives to compete more effectively with other countries for investments in R&D and manufacturing. You arrived in Turkey five months ago after working in China for two and a half years. Many executives in Turkey have…